GTG Labs (GENE) - Cumulative Company Assets

Official company branding of gtglabs.com (GENE)

The price action for Genetic Technologies (GENE) shown below on the GURU.Markets platform records total assets at 7.01. Genetic Technologies is currently suffering from a lack of stable cash flows, as cancer screenings are only beginning to generate profit. To accelerate report delivery, the business utilizes third-party IT solutions and external contractors for sample collection. The company plans to grow its market share by implementing the geneType system in private clinics.

Genetic Technologies (GENE) Company Total Assets: for the period 07/04/2022 - 10/26/2024

Analytical breakdowns for Genetic Technologies

- price and consensus price forecast:
Market Price Genetic Technologies Limited|GENE - Price Target Chart
- market capitalization data:
Market Valuation Genetic Technologies Limited|GENE - Enterprise Value
- book capitalization data:
Net Asset Value per Share Genetic Technologies|GENE - Book Capitalization|Capitalization to Book Value Ratio gtglabs.com|GENE - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Genetic Technologies|GENE - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Genetic Technologies Limited|GENE - Company Aggregate Debts|Debts to Book Capitalization Genetic Technologies Limited|GENE - Company Long-Term Debt|Company Short-Term Debt Genetic Technologies
Fundamental valuation:GTG Labs, GENE
Finished products of GTG Labs

The efficiency of the Genetic Technologies (GENE) logistics chain for the prompt delivery of tests to laboratories depends directly on the resource base, which is reflected in the total asset valuation. This indicator, reverse-calculated via ROA, aggregates equity and liabilities, allowing investors to track the actual scale of the business and identify risks of corporate over-leverage in a timely manner.

Main competitors

A (agilent.com) - Company Assets|Aggregate Company Assets DGX|Cumulative Company Assets Illumina Inc|Cologuard - Company Total Assets|Company Assets Revvity Corp (RVTY)|BIO - Company Total Assets|Total Business Assets anbio.com NNNN|Sotera Health - Company Total Assets|QDEL: Company Total Assets|Aggregate Company Assets OPKO Corp|CareDx, Inc. (CDNA) - Total Business Assets|MRVI (Maravai LifeSciences) - Company Total Assets|Company Total Assets FLGT|Aggregate Company Assets Standard BioTools (LAB)|Aggregate Company Assets Cytek Biosciences Inc CTKB|OSUR: Cumulative Company Assets|Exagen Inc - Company Assets|Aggregate Company Assets MDXH (MDxHealth SA)|LUCD - Company Total Asset Base|prenetics.com - Company Total Assets|IMDX (Insight Molecular Diagnostics Inc) - Company Total Asset Base|TRIB: Aggregate Company Assets|Company Total Asset Base ProPhase Labs Corp|AIMD: Company Total Assets|Company Balance Sheet Assets codiagnostics.com (CODX)|HSCS: Company Total Assets|Biomerica Inc. - Company Assets|Cardio Diagnostics Holdings, Inc. (CDIO) - Aggregate Company Assets|VRAX - Total Business Assets|Company Total Assets BJDX|Company Assets aspirawh.com|Accelerate Diagnostics, Inc. (AXDX) - Cumulative Company Assets|Aggregate Business Assets Centogene NV|ENZ (Enzo Biochem, Inc.) - Company Total Assets|Company Total Asset Base fresh2.co (FRES)|23andMe Holding Co. - Company Total Assets|PMD - Cumulative Company Assets